HUPO 2025

HUPO 2025
Call for Abstracts

Abstract Submission

Abstract Submission is Scheduled to Open February 2025.

Important dates

February 28, 2025 
Registration & Housing Opens

July 3, 2025
Abstract and Travel Award Notifications

February 28, 2025 
Abstract Submission and
Travel Award Application Opens

July 31, 2025 (23:59 PDT)
Early Registration Deadline

May 16, 2025 (23:59 PDT)
Abstract Submission and
Travel Award Application Deadline

September 26, 2025 (23:59 PDT) 
Regular Registration & Accommodation Booking Deadline

November 9 – 13, 2025
Congress

Abstract Submission Guidelines

  • Title (maximum 20 words) 
  • Authors and affiliations 
  • Structure the abstract body (maximum 300 words) with the following headings: 
    1. Introduction 
    2. Methods 
    3. Results 
    4. Conclusions 
    5. (References optional) 

Abstract Submission Categories

Below, you will find the list of abstract submission categories, with keywords provided to help you identify the most appropriate category for your abstract. Alternatively, you can click on “List of Keywords” to download the PDF file.

Application of Proteomics in Biopharma and Food Industry
Keywords:
Antibodies, Drugs, Biotherapeutics, Bioprocessing, Molecular Pharming, Biopharma, Diagnostics, Future Food (E.G., Cultured Food), Quality Control, Counterfeit Detection, Food Fraud 

Artificial Intelligence in Proteomics
Keywords: AI in Mass Spectrometry, Biological Insights, Classification, Data Analysis, Machine Learning, Deep Learning, Supervised Learning, Unsupervised, Learning, Reinforcement Learning, Artificial Intelligence

Cell Signaling and Proteome Dynamics
KeywordsProtein Homeostasis, Stability, Turnover, PTM Dynamics, Signal Transduction

Chemoproteomics and Drug Discovery
Keywords: Activity and Thermal Profiling, Energetics-Based Protein Separation
Biopharma, Chemoproteomics for PTM Profiling, Click Chemistry, Chemo-Enzymatic, Machine-Learning and Computational Modeling, Small Molecule Modulators, Molecular Glue, Protein Degraders

Clinical Proteomics
Keywords: AI And Computational Approaches in The Clinic
Biomarkers, Diagnostics, Prognostics
Clinical Cohorts, Clinical Trials, Population Health and Studies
Precision and Personalized Medicine
Targeted Therapies, Therapeutics, Tissue Biopsies, Body Fluids

Data Integration and Innovative Computational Methods for System Biology
KeywordsFunctional Enrichment, Differential Abundance, New Statistical Analyses
Integrative Bioinformatics
Network Biology
Novel Software, Computational Methodology, Databases and
Repositories, Annotations
Proteogenomics

Environmental and Human Microbiomes
Keywords: Bacteria, Fungi, Parasites, Viruses, Phages, Etc. Metaproteomics, Meta-Metabolomics Microbiota Source (E.G., Marine, Soil, Gut, Skin, Saliva, Microorganisms)

Glycoproteomics and Post-translational Modifications
Keywords: Chemical Modifications Glycobiology Glycosylation, Phosphorylation, Acetylation, Ubiquitination, Methylation, etc. N-terminomics, Degradomics 

Host-Pathogen, Infectious Diseases and Virology
Keywords: Antimicrobial Resistance, Bacteria, Fungi, Parasites, Viruses, Phages, etc., Immunobiology, Pandemic Preparedness

Immunopeptidomics and Immunoproteomics
Keywords: Antigen Presentation, Antibodies, Autoimmunity, HLA/MHC Class I & Class II, Immunopeptides, Immunoproteins, Method and Technology Development, Vaccination, Immunogenicity, Immune Response

Innovations in Proteomics Methodology
Keywords: Analytical Techniques, Computational Analysis, High-Throughput, Deep Proteomics, Method, Technology, and Instrumentation Development, Sample Preparation, Workflow Automation/Integration

Multi-Omics and Systems Biology
Keywords: Genomics, Transcriptomics, Metabolomics, Lipidomics, Integrative
Omics, Multi-Omics Data Integration, Network Biology and Modeling

New Technologies for Large Scale Proteomics

Non-Canonical Translation and Microproteins
Keywords: Non-Canonical Open-Reading Frames and Proteins
Novel and Alternative Proteins
Small Open Reading Frames and Proteins

Novel Computational Analysis of Mass Spectrometry Data
Keywords: Computational Methods for Data Acquisition Data Processing (E.G., De-Noising, Normalization) De Novo Sequencing Novel Search Engines, Strategies, Peptide and Proteins Identification, Open Modification Searches Quantification

One Health One World
Keywords: Animal, Human, Environmental Health, Plant and Agricultural Proteomics, Sustainability, Veterinary-Based Proteomics

Proteome Organization
Keywords: Organelles, Membranes, Extracellular Vesicles, Protein Complexes, Protein-protein Interactions, Proximal Proteomics, Cross-linking,
Secretomics, Surface Proteome

Proteomics in Human Diseases
Keywords: Aging, Cancer, Cardiovascular, Gastrointestinal Diseases, Metabolic Diseases and Diabetes, Neuroscience, Neurodegenerative Disorders, Psychiatric Disorders

Quantitative Proteomics
Keywords: Chemical and Metabolic Labeling, Data Independent Analysis and Data Dependent Analysis, Label-free Quantification, Quantitative Approach 

Single Cell Proteomics
Keywords: Low Copy Number, Mass Cytometry and Imaging, Method And Technology Development, Single Cell Multi-Omics, Single Organelle, Single Cell-Type

Spatial and Imaging Proteomics
Keywords: Imaging Processing and Analysis, Mass Spectrometry Imaging
Microscopy, Proximity Labelling, Cross-Linking, Tissue and Cell imaging

Structural Proteomics
Keywords: Chemical Footprinting, Cryo-EM
HDX, Cross-linking, Limited Proteolysis, Machine-learning and Computational Modeling, Native Mass Spectrometry, Thermal Profiling and Energetics-based Protein Separation, Protein
Folding

Technological Advancements

Top-Down Proteomics and Proteoforms
Keywords: Combinatorial Modifications, Middle-down, Native Mass Spectrometry, Protein Complexes

Applications of Proteomics in Biopharma and Food Industry
  • Antibodies, Drugs, Biotherapeutics
  • Bioprocessing, Molecular Pharming, Biopharma
  • Diagnostics
  • Future Food (E.G., Cultured Food)
  • Quality Control, Counterfeit Detection, Food Fraud
Artificial Intelligence in Proteomics
  • AI in Mass Spectrometry, Biological Insights, Classification, Data Analysis
  • Machine Learning, Deep Learning, Supervised, Learning, Unsupervised Learning, Reinforcement Learning, Artificial Intelligence
Cell Signaling and Proteome Dynamics
  • Protein Homeostasis, Stability, Turnover
  • PTM Dynamics Signal
  • Transduction
Chemoproteomics and Drug Discovery
  • Activity and Thermal Profiling, Energetics-Based Protein Separation
  • Biopharma
  • Chemoproteomics for PTM Profiling
  • Click Chemistry, Chemo-Enzymatic
  • Machine-Learning and Computational Modeling
  • Small Molecule Modulators, Molecular Glue, Protein Degraders
Clinical Proteomics
  • AI And Computational Approaches in The Clinic
  • Biomarkers, Diagnostics, Prognostics
  • Clinical Cohorts, Clinical Trials, Population Health and Studies
  • Precision and Personalized Medicine
  • Targeted Therapies, Therapeutics
  • Tissue Biopsies, Body Fluids
Data Integration and Innovative Computational Methods for System Biology
  • Functional Enrichment, Differential Abundance, New Statistical Analyses
  • Integrative Bioinformatics
  • Network Biology
  • Novel Software, Computational Methodology, Databases and Repositories, Annotations
  • Proteogenomics
Environmental and Human Microbiomes
  • Bacteria, Fungi, Parasites, Viruses, Phages, Etc.
  • Metaproteomics, Meta-Metabolomics
  • Microbiota
  • Source (E.G., Marine, Soil, Gut, Skin, Saliva, Microorganisms)
Glycoproteomics and Post-translational Modifications
  • Chemical Modifications
  • Glycobiology
  • Glycosylation, Phosphorylation, Acetylation, Ubiquitination, Methylation, etc.
  • N-terminomics, Degradomics
Host-Pathogen, Infectious Diseases and Virology
  • Antimicrobial Resistance
  • Bacteria, Fungi, Parasites, Viruses, Phages, etc.
  • Immunobiology
  • Pandemic Preparedness
Immunopeptidomics and Immunoproteomics
  • Antigen Presentation, Antibodies
  • Autoimmunity
  • HLA/MHC Class I & Class II
  • Immunopeptides, Immunoproteins
  • Method and Technology Development
  • Vaccination, Immunogenicity, Immune Response
Innovations in Proteomics Methodology
  • Analytical Techniques
  • Computational Analysis
  • High-Throughput, Deep Proteomics
  • Method, Technology, and Instrumentation Development
  • Sample Preparation
  • Workflow Automation/Integration
Multi-Omics and Systems Biology
  • Genomics, Transcriptomics, Metabolomics, Lipidomics, Integrative Omics
  • Multi-Omics Data Integration
  • Network Biology and Modeling
New Technologies for Large Scale Proteomics

TBC

Non-Canonical Translation and Microproteins
  • Non-Canonical Open-Reading Frames and Proteins
  • Novel and Alternative Proteins
  • Small Open Reading Frames and Proteins
Novel Computational Analysis of Mass Spectrometry Data
  • Computational Methods for Data Acquisition
  • Data Processing (E.G., De-Noising, Normalization)
  • De Novo Sequencing
  • Novel Search Engines, Strategies, Peptide and Proteins Identification, Open Modification Searches
  • Quantification
One Health One World
  • Animal, Human, Environmental Health
  • Plant and Agricultural Proteomics
  • Sustainability
  • Veterinary-Based Proteomics
Proteome Organization
  • Organelles, Membranes, Extracellular Vesicles, etc.
  • Protein Complexes
  • Protein-protein Interactions, Proximal Proteomics, Cross-linking
  • Secretomics
  • Surface Proteome
Proteome in Human Diseases
  • Aging
  • Cancer
  • Cardiovascular
  • Gastrointestinal Diseases
  • Metabolic Diseases and Diabetes
  • Neuroscience, Neurodegenerative Disorders, Psychiatric Disorders
Quantitative Proteomics
  • Chemical and Metabolic Labeling
  • Data Independent Analysis and Data Dependent Analysis
    Label-free Quantification
  • Quantitative Approach
Single Cell Proteomics
  • Low Copy Number
  • Mass Cytometry and Imaging
  • Method And Technology Development
  • Single Cell Multi-Omics
  • Single Organelle, Single Cell-Type
Spatial and Imaging Proteomics
  • Imaging Processing and Analysis
  • Mass Spectrometry Imaging
  • Microscopy
  • Proximity Labelling, Cross-Linking
  • Tissue and Cell imaging
Structural Proteomics
  • Chemical Footprinting
  • Cryo-EM
  • HDX, Cross-linking, Limited Proteolysis
  • Machine-learning and Computational Modeling
  • Native Mass Spectrometry
  • Thermal Profiling and Energetics-based Protein Separation, Protein Folding
Technological Advancements

TBC

Top-Down Proteomics and Proteoforms
  • Combinatorial Modifications
  • Middle-down
  • Native Mass Spectrometry
  • Protein Complexes

Frequently Asked Questions

Abstract titles will be released July 23, 2024.

The full abstract bodies will be released on August 14, 2024 at 10:00 PDT, except those abstracts included in the WCLC 2024 Press Program.  

 

Abstracts selected for inclusion in the WCLC press program, including Presidential Sessions abstracts, will be kept under embargo until either the time of the presentation or the beginning of the WCLC press conference in which it is presented, whichever comes first.  

An abstract that has previously been presented at another meeting will only be considered if there have been significant updates to the presentation. Submitters are required to list any previous presentations during the abstract submission process.

The submission of single case reports is not permitted, however, submission of case series with a minimum of 3 cases but preferably 5, including literature review is accepted. 

July 12, 2024 is the withdrawal deadline for regular abstracts and August 9 for LBA abstracts.
The presenting author registration deadline (except LBA abstracts) is July 12, 2024 (23:59 PDT). Abstract presentations for a presenter (except LBA abstracts) not registered by this date will be withdrawn from the program.

  • LBA designation will only be given to impactful prospective studies that will change clinical practice within the year and whose data are not available at the time of regular abstract submission due to study events and/or timelines. Examples include randomized phase II and/or III trials, and large single arm phase II trials in rare subtypes of thoracic malignancies. LBA’s in other disciplines that change clinical practice within the year will also be considered.
  • LBA designation is not a means for extending the regular abstract deadline. Highly impactful studies that have complete data should be submitted as a regular abstract and will be considered for a prominent oral presentation based on scoring by the program committee.
  • For abstracts that do not meet LBA requirements the authors will be given 48 hours to update the submitted data before the abstracts are re-classified as regular abstracts and rated based on the updated information.

Yes, industry is permitted to be in the lead and senior author positions in the author list of an abstract. However, Industry/pharmaceutical/commercial authors are prohibited from presenting Presidential, Oral, and Mini Oral presentations. Industry/pharmaceutical/commercial authors are permitted to present poster or e-poster presentations. 

Associated manuscripts for any abstract selected for presentation at WCLC can be submitted to a peer reviewed journal prior to presentation at WCLC but must not be published prior to the presentation at WCLC. Simultaneous publications are encouraged. 

All Regular Abstracts, Clinical Trials in Progress Abstracts, and Case Series abstracts must be fully completed by the April 5, 2024 deadline.

Any Regular Abstracts and Case Series that are incomplete after the April 5, 2024 deadline will be automatically withdrawn and will not be considered for the meeting. Clinical Trials in Progress abstracts may be submitted and completed by the April 5, 2024 deadline without Results and Conclusions as those sections are optional for CTPS submissions.

To submit a late breaking abstract, you must submit a placeholder abstract including all components of the abstract except for the Results and Conclusions by the April 5, 2024 deadline.

Authors can only be listed as the Presenting Author on two (2) abstracts but can be co-author on any number of abstracts. 

The authors of the abstract, however, IASLC reserves the right to sell and retain any revenue/income from selling the abstracts, presentation materials or recordings of the presentations. Please refer to the detailed terms and conditions that authors have to agree to during the abstract submission.

Copyright is with the authors, however, IASLC reserves the right to publish and sell copies/recordings of the presentation materials.

The clinical trials must be registered in clinicaltrials.gov or an applicable one from their country/regulatory body.

No. You need to attend WCLC 2024 in person to present your abstract.

The video platform will be available for 3 months after WCLC.

contact Us

For inquiries, please contact hupo2025-program@icsevents.com

Scroll to Top